Erin E. Tapper

Medicine · Health Sciences

10h-index425citations92works1.82yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(66), Phagocytosis and Immune Regulation(31), Virus-based gene therapy research(11), Colorectal Cancer Treatments and Studies(8), Epigenetics and DNA Methylation(5)

Publications92 total

Supplementary Table S1 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025Open Access
Supplementary Figure Legends from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025Open Access
Supplementary Figures from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025Open Access
Supplementary Table S2 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025Open Access
Results of Multigene Panel Testing, Including PKD1, in >1,200 Patients With Cystic Kidney Disease: A Retrospective Analysis
Kidney Medicine·2025Open Access
Supplementary Figure Legends from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Figure Legends from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Table S1 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Figures from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Table S1 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Table S2 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Table S2 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Figures from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Data from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
OPTIMIZATION OF TSHR-CART CELL THERAPY TO TRANSLATE INTO A FIRST IN HUMAN PHASE I CLINICAL TRIAL IN METASTATIC THYROID CANCERS
Cytotherapy·2024
Mesenchymal stromal cells with chimaeric antigen receptors for enhanced immunosuppression
Nature Biomedical Engineering·2024· 30 citedOpen Access
Abstract 3849: Frontline ibrutinib-based therapy enhances CART cell functions in patients with CLL: Analysis of the phase 3 randomized clinical trial ECOG-ACRIN E1912
Cancer Research·2024Open Access
Supplementary Figures from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2023Open Access
Supplementary Figure Legends from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2023Open Access
Supplementary Table S2 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Michelle J. Cox(41), Kendall J. Schick(41), Saad S. Kenderian(41), Reona Sakemura(40), Mehrdad Hefazi(39), Michael W. Ruff(38), Claudia Manriquez Roman(37), Neil E. Kay(36), Sameer A. Parikh(34), Elizabeth L. Siegler(32), Paulina Horvei(31), İsmail Can(30), Evandro D. Bezerra(28), Lionel Aurelien Kankeu Fonkoua(28), Mohamad M. Adada(26), Michael J. Hansen(23), Carli M. Stewart(23), Wendy K. Nevala(19), Justin C. Boysen(17), Wei Ding(17)